UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 30, 1997 XOMA CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-14710 94-2756657 (Commission File Number) (IRS Employer Identification No.) 2910 Seventh Street, Berkeley, California 94710 (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code (510) 644-1170 None (Former name or former address, if changed since last report) -2- Item 5. Other Events On January 8, 1998, XOMA Corporation issued the announcement attached hereto as Exhibit 1, which is incorporated herein by reference. Item 7. Exhibits 1. Press Release dated January 8, 1998 2. Patent and Exclusive License Purchase Agreement by and between Pharmaceutical Partners, L.L.C. and XOMA Corporation dated as of December 30, 1997 -3- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 9, 1998 XOMA CORPORATION By:/s/ Peter B. Davis ------------------------------- Peter B. Davis Vice President, Finance and Chief Financial Officer -4- EXHIBIT INDEX Number Description 1. Press Release dated January 8, 1998 2. Patent and Exclusive License Purchase Agreement by and between Pharmaceutical Partners, L.L.C. and XOMA Corporation dated as of December 30, 1997